CORE--CLINICAL AND RESEARCH

核心——临床与研究

• 批准号: 6479983
• 负责人: KATHLEEN Anne WELSH-BOHMER
• 金额: $ 31.39万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-08-01 至 2002-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6479983
• 关键词: Alzheimer's disease; bioimaging /biomedical imaging; biomedical facility; brain disorder diagnosis; brain imaging /visualization /scanning; clinical research; computed axial tomography; dementia; diagnosis design /evaluation; diagnosis quality /standard; disease /disorder onset; family genetics; genetic susceptibility; human subject; human tissue; longitudinal human study; magnetic resonance imaging; medical outreach /case finding; memory disorders; phenotype; postmortem; twin /multiplet

The continuing scientific progress in Alzheimer's disease (AD) relies on the availability of carefully evaluated patients and controls for study. The main goal of the Clinical Research Development Core is to facilitate genetic family studies and other multi-disciplinary efforts of the Bryan ADRC by providing the basic diagnostic assessment of patients with memory complaints. We have evaluated over 5000 new patients in the Neurological Disorders Clinic (NDC) of the Bryan ADRC since 1990. We plan to focus on continued high-quality evaluation and treatment of patients with AD and other related dementias. We also propose methods to continue to develop our multi-cultural clinical services to elderly African American and other people of color in the community. Identify families for genetic studies of AD and other late onset dementias. There are over 75 families enrolled in the Center in which there is multi- generated evidence of AD with autopsy confirmation. We plan to continue to develop and evaluate additional informative families. In conjunction with the Duke Center for Human Genetics (DCHG), we also intend to study unaffected siblings of AD patients using new genetic methods of sib-pair analysis, in an effort to identify other susceptibility genes. Continue the active enrollment of selected patients and normal controls in the Bryan ADRC autopsy program. Currently, we conduct at least 70 autopsies per year and follow over 100 patients with AD and approximately 200 non-demented controls. During the grant period we will continue our current enrollment and clinical evaluation practices but we will also make a strong focused effort on increasing minority enrollment in both the normal control and dementia protocols of the autopsy program. Facilitate clinical research studies of Alzheimer's disease. The Clinical Core will continue to be a resource to the research studies of the Bryan ADRC, and to external studies continues to be to define the earliest clinical phenotype of AD through systematic longitudinal study of cognitively normal subjects at enhanced risk of AD.

阿尔茨海默病 (AD) 的持续科学进步依赖于仔细评估的患者和对照研究的可用性。临床研究开发核心的主要目标是通过为记忆障碍患者提供基本诊断评估，促进 Bryan ADRC 的遗传家族研究和其他多学科工作。自 1990 年以来，我们已经在 Bryan ADRC 的神经疾病诊所 (NDC) 评估了 5000 多名新患者。我们计划重点关注对 AD 和其他相关痴呆症患者的持续高质量评估和治疗。我们还提出了继续为社区中的老年非裔美国人和其他有色人种发展我们的多元文化临床服务的方法。确定 AD 和其他迟发性痴呆症的遗传研究家族。该中心登记了超过 75 个家庭，其中有经过尸检确认的多种 AD 证据。我们计划继续开发和评估更多信息丰富的家庭。我们还打算与杜克大学人类遗传学中心 (DCHG) 合作，利用新的同胞对分析遗传方法来研究 AD 患者未受影响的兄弟姐妹，以期找出其他易感基因。继续在 Bryan ADRC 尸检项目中积极招募选定的患者和正常对照。目前，我们每年至少进行 70 次尸检，并对 100 多名 AD 患者和大约 200 名非痴呆对照患者进行随访。在拨款期间，我们将继续目前的招募和临床评估实践，但我们也将大力致力于增加尸检计划正常对照和痴呆方案中少数族裔的注册人数。促进阿尔茨海默病的临床研究。临床核心将继续成为 Bryan ADRC 研究的资源，而外部研究则继续通过对 AD 风险较高的认知正常受试者进行系统纵向研究来定义 AD 的最早临床表型。